Eli Lilly and Company Q2 2026 Earnings Call Summary
| | | |

Eli Lilly and Company Q2 2026 Earnings Call Summary

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we’ll show you why it’s our #1 pick. Tap here. Revenue growth of 48% was primarily catalyzed by the massive scale-up of Zepbound and Mounjaro, which contributed $6.3 billion in incremental growth compared to the…

Magnum (MICC) Q2 2026 Earnings Call Transcript
| | | |

Magnum (MICC) Q2 2026 Earnings Call Transcript

Our vision for The Magnum Ice Cream Company is simple. We want to make the most loved ice cream in the world to grow the market and build a highly competitive snacking business for our shareholders and customers. And we will do that by delivering our strategy to grow the ice cream market as category…

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat
| | | |

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

Gilead Sciences’ (GILD) highly anticipated HIV prevention drug, Yeztugo, beat second-quarter expectations late Tuesday, allaying analysts’ concerns over soft prescription trends. However, Gilead stock toppled Wednesday. The Street’s focus landed on HIV treatment powerhouses Biktarvy and Descovy. The duo “beat considerably, even if helped somewhat by pricing and favorable inventory … and seasonal dynamics,” RBC…

SpaceX And Tesla Earnings Have A Similar Theme: Capex Spending
| | | |

SpaceX And Tesla Earnings Have A Similar Theme: Capex Spending

SpaceX earnings impressed, but did little to the young, moribund stock. Any investors hoping the report might do have done the same for the languishing shares of Elon Musk’s other company, Tesla, were also disappointed. SpaceX (SPCX) stock fell 13.6% on Wednesday, according to MarketSurge. Tesla (TSLA) slipped 1.8%. SpaceX reported earnings for the first…

Amgen Hikes Sales Outlook By  Billion After Second-Quarter Smash
| | | |

Amgen Hikes Sales Outlook By $1 Billion After Second-Quarter Smash

Amgen (AMGN) stock popped Wednesday on what one analyst called an “impressive” quarter featuring double-digit growth for nearly two dozen of its products. The best growth came from Uplizna, a treatment for several rare autoimmune conditions. Sales nearly doubled, rocketing 90% to $335 million. Meanwhile, revenue from the company’s biggest moneymaker, cholesterol drug Repatha, surged…

Mortgage retreat, still near one-year high
| | | |

Mortgage retreat, still near one-year high

Mortgage rates fell this week, with the 30-year fixed rate averaging 6.63%, down from 6.67% last week, according to Bankrate’s latest lender survey. Current mortgage rates The 30-year fixed mortgages in this week’s survey had an average total of 0.26 discount and origination points. Discount points are a way to lower your mortgage rate, while…

Strategy’s Preferred Stock Recovers As Company Builds Cash Reserve
| | | |

Strategy’s Preferred Stock Recovers As Company Builds Cash Reserve

Strategy’s (NASDAQ: $MSTR) high-yielding preferred stock (NASDAQ: $STRC) is recovering as the serial cryptocurrency acquirer prioritizes building up its cash reserves.  The preferred stock is trading at $94 U.S. on Aug. 5, having gained 6% in the last five trading sessions and risen more than 30% from its June low.  STRC stock bottomed in late…

Dollar Slides on Stock Strength and Weakness in US Economic Reports
| | | |

Dollar Slides on Stock Strength and Weakness in US Economic Reports

The dollar index (DXY00) fell by -0.17% on Wednesday.  The dollar fell on Wednesday after the S&P 500 climbed to a new record high, reducing demand for dollar liquidity.  Also, Wednesday’s weaker-than-expected reports on July ADP employment and July ISM services were bearish for the dollar.  Losses in the dollar are limited on hawkish comments…

Eli Lilly stock soars on strong demand for weight-loss drugs
| | | |

Eli Lilly stock soars on strong demand for weight-loss drugs

What happened: Eli Lilly (LLY) stock jumped as much as 7% on Wednesday. What’s behind the move: The drug company raised its 2026 sales forecast after it saw strong demand for GLP-1 drugs in its fiscal second quarter. Revenue is now expected to fall between $85 billion and $87 billion for the year, topping an earlier…

Exclusive-‘No discussions’ over AstraZeneca-Bristol Myers deal, senior source says
| | | |

Exclusive-‘No discussions’ over AstraZeneca-Bristol Myers deal, senior source says

By Maggie Fick and Sabrina Valle Aug 5 (Reuters) – There are “no discussions” ongoing between AstraZeneca and Bristol Myers Squibb over a ‌potential deal, a senior source close to the matter told ‌Reuters on Wednesday, quashing the prospect of a mooted mega merger between the drugmakers. “There ​is no deal between AstraZeneca and BMS….

End of content

End of content